Evenity Side Effects: Common, Serious, and Rare

Evenity (romosozumab) causes injection-site reactions in a substantial number of users, along with joint pain and headaches, but the side effect that draws the most attention is a cardiovascular safety signal serious enough to earn an FDA boxed warning. The drug is one of the more powerful osteoporosis treatments available, building new bone at a pace other drugs cannot match, yet that potency comes with a side-effect profile that requires careful screening before and monitoring during its limited 12-month treatment window.

How the Drug Works and Why That Matters for Side Effects

Evenity is a monoclonal antibody that targets a protein called sclerostin. Sclerostin normally acts as a brake on bone formation. By binding to sclerostin and taking it out of action, Evenity releases that brake: bone-building cells ramp up their activity, and at the same time, bone-resorbing cells slow down slightly.¹ This dual effect is unusual among osteoporosis drugs, most of which either build bone or slow its breakdown, but not both at once.²

Understanding this mechanism matters for side effects because sclerostin is not found only in bone. It is also expressed in the heart, the aorta, coronary arteries, and peripheral blood vessels.³ Blocking sclerostin everywhere in the body, not just in bone, is likely the reason cardiovascular concerns have followed this drug since its earliest large trials.

Common Side Effects

Evenity is given as two subcutaneous injections once a month, and the most frequent complaints relate to the injection itself. Soreness, redness, or swelling at the injection site are reported commonly and usually resolve within a few days. A meta-analysis comparing romosozumab to teriparatide (another bone-building drug) actually found that injection-site reactions were significantly more common with teriparatide, suggesting Evenity’s local reactions, while frequent, tend to be milder than those of some alternatives.⁴

Beyond the injection site, the most commonly reported side effects in clinical trials include joint pain (arthralgia), headache, and muscle spasms. These tend to be mild to moderate in intensity. A large pharmacovigilance analysis of FDA adverse-event reports from 2019 to 2023, covering more than 7,000 reports where romosozumab was the primary suspect, confirmed that musculoskeletal and connective tissue complaints were among the top three categories of reported problems.⁵ That same analysis also flagged gastrointestinal and respiratory complaints as “unexpected” adverse event categories, meaning they showed up in the real-world data more than the original clinical trials had suggested they would.⁶

Skin reactions beyond simple injection-site soreness can occasionally be more dramatic. In one published case, a patient developed severe erythematous-oedematous plaques with well-defined borders around the injection area after just one dose, leading to immediate discontinuation of the drug after evaluation by multiple specialists.⁷ This kind of severe skin reaction appears to be uncommon, but it highlights that any unusual rash or swelling after an injection should be evaluated promptly.

The Cardiovascular Warning

The most consequential safety issue with Evenity is a potential increase in cardiovascular events, specifically heart attack, stroke, and cardiovascular death. This concern emerged from the ARCH trial, which compared romosozumab to alendronate (a bisphosphonate) in postmenopausal women at high fracture risk. In that study, patients on romosozumab had a significantly higher rate of serious cardiovascular events than those on alendronate.⁸ The finding was striking enough that both the FDA and the European Medicines Agency initially refused marketing authorization. The FDA eventually approved the drug in 2019, but with a boxed warning, the most serious type of safety alert, cautioning against use in patients who have had a heart attack or stroke within the past year.

Europe went further. The European Medicines Agency treats any history of heart attack or stroke, not just a recent one, as a contraindication.⁹ This difference in regulatory stance reflects genuine uncertainty about how large the cardiovascular risk truly is, and whether the ARCH trial results were partly influenced by the comparator arm rather than a direct harmful effect of romosozumab itself.

A pharmacovigilance study using the FDA’s adverse event reporting system found elevated reporting of major adverse cardiovascular events associated with romosozumab, with a reporting odds ratio of about 4, driven largely by reports from Japan, where the drug was first approved and most widely used in its early years.¹⁰ It is worth noting that pharmacovigilance databases capture reports rather than prove causation, and a drug under heightened scrutiny will naturally attract more reporting. Still, the signal has been consistent enough across multiple data sources that the concern is taken seriously by every prescribing physician.

Why Sclerostin Matters to Blood Vessels

The cardiovascular concern is not just a statistical anomaly from a single trial. There is a biological rationale behind it. Sclerostin, the protein Evenity blocks, appears to play a protective role in blood vessels. Animal studies have found that sclerostin is expressed at sites of arterial calcification, the hardening of artery walls that contributes to cardiovascular disease.³ Research in mice has provided evidence that sclerostin actually protects against vascular calcification as it develops.¹¹

Sclerostin has also been identified as a marker for both clinical and subclinical vascular disease, suggesting it plays an active role in the blood vessel wall’s response to damage rather than just being a bystander.¹² If sclerostin is helping to keep arterial calcification in check, blocking it with a drug could theoretically accelerate calcification in people whose arteries are already vulnerable. This would explain why the risk seems concentrated in patients with pre-existing cardiovascular disease and why regulators have drawn hard lines around who should receive the drug.

That said, real-world data from Japan, where romosozumab has been in clinical use the longest, offers some reassurance. A post-marketing surveillance analysis covering more than 39,000 person-years of exposure found that the rate of strokes was about 0.16 per 100 person-years and the rate of ischemic heart events was about 0.10 per 100 person-years. Both numbers were lower than the background rates seen in general population cohort studies in Japan, suggesting that when physicians screen patients appropriately, the real-world risk may be manageable.¹³

Calcium Drops and Parathyroid Hormone Spikes

Evenity can cause transient dips in blood calcium levels, which in turn trigger a rise in parathyroid hormone as the body tries to restore calcium balance. For most patients with normal kidney function, these shifts are mild and self-correcting, barely noticeable. But in patients with impaired kidneys, the picture changes substantially. A study examining the effects of a single dose of romosozumab across different levels of kidney function found that people with severe kidney impairment and those on dialysis were far more likely to experience drops in serum calcium and spikes in parathyroid hormone compared to healthy volunteers.¹⁴ All cases of hypocalcemia in that study were asymptomatic, but the finding underlines why calcium and vitamin D levels should be corrected before starting treatment, and why kidney function matters when weighing Evenity’s risks.

The real-world FAERS analysis also flagged elevated parathyroid hormone as a notable post-marketing signal, appearing with high signal strength even though it was infrequent in absolute terms.⁵ For patients already dealing with hyperparathyroidism or chronic kidney disease, this is a meaningful consideration.

Rare but Serious Adverse Events

Two rare complications associated with long-term use of some osteoporosis drugs are atypical femoral fractures and osteonecrosis of the jaw. Atypical femoral fractures are unusual stress fractures of the thigh bone, strongly linked to prolonged bisphosphonate use. A study using the FDA’s adverse event database found that romosozumab was not associated with increased reporting of atypical femoral fractures in the available data.¹⁵ Given that Evenity is only used for 12 months, while atypical femoral fractures typically emerge after years of bone-resorption suppression, this makes biological sense. However, many patients transition from Evenity to a bisphosphonate afterward, so cumulative exposure to bone-resorption drugs over a lifetime is still worth tracking.

Osteonecrosis of the jaw, where a section of jawbone fails to heal properly, is another concern associated with drugs that suppress bone resorption. Evenity’s primary action is bone formation rather than resorption suppression, so the risk appears to be very low during the 12-month course. No strong signal for osteonecrosis of the jaw has emerged from the major pharmacovigilance analyses, though case reports exist in the literature for virtually all osteoporosis drugs and vigilance is still warranted, especially for patients undergoing invasive dental procedures.

The FAERS analysis identified a few adverse events that were not part of the original product labeling but appeared in post-market data with notable signal strength. These included decreased serum procollagen type I N-terminal propeptide (a bone formation marker, suggesting the drug’s bone-building effect can diminish), increased tartrate-resistant acid phosphatase (a marker of bone resorption), and pseudarthrosis (failure of a fracture to heal). While rare in absolute numbers, each showed high signal strength, meaning they appeared disproportionately often in romosozumab reports compared to the broader adverse-event database.⁵ Aortic dissection, a rare but life-threatening tearing of the wall of the aorta, also appeared in this analysis as a notable signal. Whether it reflects a genuine drug effect or the cardiovascular vulnerability of the patient population being treated remains an open question.

Comparing Evenity’s Safety to Other Bone-Building Drugs

Patients are often offered a choice between Evenity and teriparatide or abaloparatide, which are parathyroid hormone analogues that also build new bone. A systematic review and meta-analysis comparing romosozumab head-to-head against teriparatide found no significant difference in the rate of serious adverse events or death at 12 months.⁴ The main difference that did emerge was injection-site reactions, which were actually more common with teriparatide.

The cardiovascular story differs between these classes, though. Parathyroid hormone analogues have no known adverse cardiovascular effects, which is one reason a propensity-score-matched cohort study chose them as a comparator for evaluating romosozumab’s cardiovascular safety.⁹ That study design tried to account for a “healthy user bias” by excluding patients who had already experienced a cardiovascular event in the prior year, since romosozumab’s boxed warning would steer sicker patients away from it. The researchers acknowledged that this bias complicates any real-world comparison: if the healthiest patients are more likely to receive Evenity, then its cardiovascular event rate in observational data might look artificially low.

What Happens When the 12-Month Course Ends

Evenity is approved for a maximum of 12 monthly doses. One practical concern that sits at the intersection of efficacy and safety is what happens to bone density after the drug is stopped. A review of bone mineral density loss after discontinuation of various osteoporosis drugs found that romosozumab, along with denosumab, showed some of the largest decreases in bone density after treatment ended, with losses of at least 1% at the femoral neck and total hip.¹⁶ This is why treatment guidelines almost universally recommend transitioning to an antiresorptive drug, typically a bisphosphonate or denosumab, after the Evenity course is complete. Without that follow-on treatment, the bone gains can erode quickly.

The sequence of treatment matters too. Research suggests that starting Evenity after stopping denosumab may be less effective than starting Evenity after a bisphosphonate, because the rebound in bone turnover that occurs after denosumab cessation can overwhelm romosozumab’s antiresorptive effect.¹⁷ In practical terms, if you are currently on denosumab and your doctor is considering adding Evenity, the timing and transition plan need to be thought through carefully.

Who Should Avoid Evenity

The clearest group of patients who should not receive Evenity includes anyone with a recent heart attack, stroke, or other serious cardiovascular event. The FDA draws the line at events within the past year, while European regulators apply the restriction to any history of myocardial infarction or stroke regardless of timing.⁹ Low calcium levels (hypocalcemia) must be corrected before starting treatment, and patients with severe kidney impairment need particularly close monitoring given their heightened susceptibility to calcium and parathyroid hormone disturbances.¹⁴

For patients who fall into a gray zone, such as those with well-controlled cardiovascular risk factors but no prior events, the decision often comes down to a conversation about the severity of their osteoporosis. Evenity is generally reserved for people at very high fracture risk, including those who have already fractured, those with very low bone density scores, or those who have not responded well to other treatments. In these patients the risk of a hip or vertebral fracture, which carries its own significant mortality, may outweigh the potential cardiovascular concern. This calculus changes patient by patient, and the Japanese post-marketing experience suggests that appropriate screening can keep event rates below general population averages.¹³

Gastrointestinal and Respiratory Signals

One finding from real-world surveillance that deserves more attention is the emergence of gastrointestinal and respiratory adverse events as significant signals in the FAERS database. Neither category was prominent in the original clinical trials, and the prescribing label does not highlight them. Yet across more than 7,000 adverse-event reports, gastrointestinal disorders and respiratory, thoracic, and mediastinal disorders appeared with enough frequency and statistical signal strength to be flagged as unexpected.⁶

Whether these represent a genuine drug effect or reflect the comorbidities of older patients with severe osteoporosis is not yet clear. Many patients on Evenity are also taking bisphosphonates or other medications with known GI side effects, and the older population being treated is inherently more prone to respiratory illness. But the signals are strong enough that future studies will likely need to examine them specifically. If you are taking Evenity and develop persistent stomach pain, nausea, or breathing difficulties that seem new, bring them up with your prescriber even if they do not seem bone-related.

1
PubMed Central. Profile of romosozumab and its potential in the management of osteoporosis
2
PubMed. Pharmacological characteristics and clinical study results of romosozumab (EVENITY; genetical recombination), a drug with novel mechanism of action to treat osteoporosis at high risk of fracture
3
PubMed. Role of Sclerostin in Cardiovascular Disease
4
PubMed Central. Romosozumab versus Teriparatide for the Treatment of Postmenopausal Osteoporosis: A Systematic Review and Meta‐analysis through a Grade Analysis of Evidence
5
PubMed Central. Romosozumab adverse event profile: a pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS) from 2019 to 2023
6
SpringerLink. Romosozumab adverse event profile: a pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS) from 2019 to 2023
7
PubMed Central. When Skin Reactions Interrupt Bone Therapy: Severe Cutaneous Adverse Reaction to Romosozumab Leading to Treatment Discontinuation
8
Journal of Bone and Mineral Research. Serious Adverse Events With Romosozumab Use in Japanese Patients: Need for Clear Formulation of Contraindications Worldwide
9
The Journal of Clinical Endocrinology & Metabolism. Cardiovascular Safety of Romosozumab vs PTH Analogues for Osteoporosis Treatment: A Propensity-Score-Matched Cohort Study
10
PubMed Central. Cardiovascular Safety Profile of Romosozumab: A Pharmacovigilance Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS)
11
Journal of Bone and Mineral Research. Sclerostin Protects Against Vascular Calcification Development in Mice
12
PubMed Central. Sclerostin and Vascular Pathophysiology
13
Osteoporosis and Sarcopenia. Romosozumab and cardiovascular safety in Japan
14
PubMed Central. Influence of Renal Function on Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Romosozumab
15
Scientific Reports. Atypical femur fracture associated with common anti-osteoporosis drugs in FDA adverse event reporting system
16
PubMed Central. Bone Mineral Density Loss and Fracture Risk After Discontinuation of Anti-osteoporotic Drug Treatment: A Narrative Review
17
PubMed Central. Romosozumab and antiresorptive treatment: the importance of treatment sequence